Encouragingly, the recent KEYNOTE-811 phase 3 randomized trial reported that addition of pembrolizumab to trastuzumab and chemotherapy resulted in a substantial, statistically significant increase in ORR versus trastuzumab and chemotherapy alone for untreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic GC; responses were durable and safety was manageable (95). The gene discussed is ERBB2; the disease is gastric cancer.